weight regain and cardiometabolic effects after withdrawal of semaglutide Regain: Prevention Strategies GLP-1 Weight regain and cardiometabolic effects

The research backing its use for other diseases, such as kidney disease (and) mental health addiction, to name a few, is extremely promising, I definitely foresee the FDA to continue to approve GLP-1s for use to combat other issues. Dr

Semaglutide, a GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, is typically supplied in pre-filled pens that display doses in milligrams

Lower doses of semaglutide were not equivalent to higher doses of tirzepatide

Its important to note, however, that the highest dose for semaglutide is now 2.2 mg (versus 1 mg used in the study), so more direct comparison is needed

There were two severe hypoglycemia events in each group and no diabetic ketoacidosis was reported